Next Article in Journal
Trends and Perspectives in Immunosensors for Determination of Currently-Used Pesticides: The Case of Glyphosate, Organophosphates, and Neonicotinoids
Previous Article in Journal
A Molecular Interaction Analysis Reveals the Possible Roles of Graphene Oxide in a Glucose Biosensor
Article Menu

Export Article

Open AccessArticle
Biosensors 2019, 9(1), 19; https://doi.org/10.3390/bios9010019

Integrated Microfluidic Devices Fabricated in Poly (Methyl Methacrylate) (PMMA) for On-site Therapeutic Drug Monitoring of Aminoglycosides in Whole Blood

1
Australian Centre for Research on Separation Science (ACROSS), School of Natural Sciences-Chemistry, University of Tasmania, Private Bag 75, Hobart, Tasmania 7001, Australia
2
College of Agriculture, University of Misan, Al-amarah, Misan 62001, Iraq
*
Author to whom correspondence should be addressed.
Received: 21 November 2018 / Revised: 18 December 2018 / Accepted: 19 December 2018 / Published: 30 January 2019
(This article belongs to the Special Issue Microfluidics for Biosensing and Diagnostics)
Full-Text   |   PDF [1578 KB, uploaded 30 January 2019]   |  

Abstract

On-site therapeutic drug monitoring (TDM) is important for providing a quick and accurate dosing to patients in order to improve efficacy and minimize toxicity. Aminoglycosides such as amikacin, gentamicin, and tobramycin are important antibiotics that have been commonly used to treat infections of chronic bacterial infections in the urinary tract, lung, and heart. However, these aminoglycosides can lead to vestibular and auditory dysfunction. Therefore, TDM of aminoglycosides is important due to their ototoxicity and nephrotoxicity. Here, we have developed a hot embossed poly (methyl methacrylate) (PMMA) microfluidic device featuring an electrokinetic size and mobility trap (SMT) to purify, concentrate, and separate the aminoglycoside antibiotic drugs amikacin, gentamicin, and tobramycin. These drugs were separated successfully from whole blood within 3 min, with 30-fold lower detection limits compared to a standard pinched injection. The limit of detections (LOD) were 3.75 µg/mL for gentamicin, 8.53 µg/mL for amikacin, and 6.00 µg/mL for tobramycin. These are sufficient to cover the therapeutic range for treating sepsis of 6–10 μg/mL gentamicin and tobramycin and 12–20 μg/mL of amikacin. The device is simple and could be mass produced via embossing or injection molding approaches. View Full-Text
Keywords: therapeutic drug monitoring (TDM); aminoglycosides; size and mobility traps (SMT) therapeutic drug monitoring (TDM); aminoglycosides; size and mobility traps (SMT)
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary material

SciFeed

Share & Cite This Article

MDPI and ACS Style

Al-aqbi, Z.T.; Yap, Y.C.; Li, F.; Breadmore, M.C. Integrated Microfluidic Devices Fabricated in Poly (Methyl Methacrylate) (PMMA) for On-site Therapeutic Drug Monitoring of Aminoglycosides in Whole Blood. Biosensors 2019, 9, 19.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Biosensors EISSN 2079-6374 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top